092 Real-World Data on Efficacy, Safety and Persistence of Dupilumab: an Analysis from the TREATgermany Registry

In clinical trials safety and efficacy of therapies are tested in selected patient populations, whereas clinical registries like the atopic dermatitis (AD) multicenter registry TREATgermany provide longitudinal patient data under real-life conditions. In this analysis data of 1211 patients (data release July 2021) with moderate to severe AD was used, with following mean scores at baseline: EASI 16.1±12.9, IGA 3.2±1.1, itch NRS 5.7±2.8, POEM 16.8±7.6, and DLQI 11.8±7.8. During observation in the registry 76.3% of patients received at least one systemic treatment for AD; with a proportion of 81.9% dupilumab was the most used drug in July 2021. In contrast, until the launch of dupilumab in Germany in December 2017 only 36.8% of patients had received at least one systemic therapy, with cyclosporine being the most often prescribed one. Dupilumab (n=369) and cyclosporine (n=41) treatments showed comparable effectiveness. Exemplary at month 12 after dupilumab initiation, EASI50, EASI75 and EASI90 were 86.3%, 68.0% and 39.1%, respectively. Discontinuation rates of cyclosporine were considerably higher. While dupilumab treatment was discontinued in 5.0% and 11.4% of the patients until month 12 and 24, cyclosporine was discontinued in 77.8% and 100%, respectively. Low persistence of cyclosporine may also reflect adherence to guideline recommendations on the duration on its continuous use. Adverse events were reported in 42.5% of all dupilumab-treated patients, ocular side effects being most frequent (29.8%). These results demonstrate that dupilumab has rapidly emerged as the most commonly used systemic treatment in Germany, and shows robust long-term efficacy and safety.